AbCellera Biologics Inc. (ABCL) income statement
ABCLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30143% above fair value
$9.69−0.78 (-7.45%)
Close on Nov 20, 2026Market cap $2.97BP/E –Yield –
AbCellera Biologics Inc. financial ratios
See a number that looks wrong?